Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 5 October 1990:
Vol. 250. no. 4977, pp. 113 - 116
DOI: 10.1126/science.2218501
Prev | Table of Contents | Next

Articles

Science, Vol 250, Issue 4977, 113-116
Copyright © 1990 by American Association for the Advancement of Science

articles

Different tumor-derived p53 mutants exhibit distinct biological activities

O Halevy, D Michalovitz, and M Oren

Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

In its wild-type form, the protein p53 can interfere with neoplastic processes. Tumor-derived cells often express mutant p53. Full-length mutant forms of p53 isolated so far from transformed mouse cells exhibit three common properties in vitro: loss of transformation-suppressing activity, gain of pronounced transforming potential, and ability to bind the heat shock protein cognate hsc70. A tumor-derived mouse p53 variant is now described, whose site of mutation corresponds to a hot spot for p53 in human tumors. While absolutely nonsuppressing, it is only weakly transforming and exhibits no detectable hsc70 binding. The data suggest that the ability of a p53 mutant to bind endogenous p53 is not the sole determinant of its oncogenic potential. The data also support the existence of gain-of-function p53 mutants.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer.
A. W. Tolcher, D. Hao, J. de Bono, A. Miller, A. Patnaik, L. A. Hammond, L. Smetzer, J. Van Wart Hood, J. Merritt, E. K. Rowinsky, et al. (2006)
J. Clin. Oncol. 24, 2052-2058
   Abstract »    Full Text »    PDF »
Aberrant p53 Expression in Feline Vaccine-associated Sarcomas and Correlation with Prognosis.
A. E. Hershey, R. R. Dubielzig, M. L. Padilla, and S. C. Helfand (2005)
Vet. Pathol. 42, 805-811
   Abstract »    Full Text »    PDF »
Induction of Invasive Mouse Skin Carcinomas in Transgenic Mice with Mutations in Both H-ras and p53.
Z. Zhang, R. Yao, J. Li, Y. Wang, C. W. Boone, R. A. Lubet, and M. You (2005)
Mol. Cancer Res. 3, 563-574
   Abstract »    Full Text »    PDF »
TP53 Mutations and Outcome in Osteosarcoma: A Prospective, Multicenter Study.
J. S. Wunder, N. Gokgoz, R. Parkes, S. B. Bull, S. Eskandarian, A. M. Davis, C. P. Beauchamp, E. U. Conrad, R. J. Grimer, J. H. Healey, et al. (2005)
J. Clin. Oncol. 23, 1483-1490
   Abstract »    Full Text »    PDF »
Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function.
L. Weisz, A. Zalcenstein, P. Stambolsky, Y. Cohen, N. Goldfinger, M. Oren, and V. Rotter (2004)
Cancer Res. 64, 8318-8327
   Abstract »    Full Text »    PDF »
p63 and p73: Roles in Development and Tumor Formation.
U. M. Moll and N. Slade (2004)
Mol. Cancer Res. 2, 371-386
   Abstract »    Full Text »    PDF »
Cooperation of Two Mutant p53 Alleles Contributes to Fas Resistance of Prostate Carcinoma Cells.
K. V. Gurova, O. W. Rokhlin, A. V. Budanov, L. G. Burdelya, P. M. Chumakov, M. B. Cohen, and A. V. Gudkov (2003)
Cancer Res. 63, 2905-2912
   Abstract »    Full Text »    PDF »
Chromosomal Instability Rather Than p53 Mutation Is Associated with Response to Neoadjuvant Cisplatin-based Chemotherapy in Gastric Carcinoma.
K. Ott, H. Vogelsang, J. Mueller, K. Becker, M. Muller, U. Fink, J. R. Siewert, H. Hofler, and G. Keller (2003)
Clin. Cancer Res. 9, 2307-2315
   Abstract »    Full Text »    PDF »
Autocrine Interleukin-6 Production in Renal Cell Carcinoma: Evidence for the Involvement of p53.
L. S. Angelo, M. Talpaz, and R. Kurzrock (2002)
Cancer Res. 62, 932-940
   Abstract »    Full Text »    PDF »
The Emerging p53 Gene Family.
W. G. Kaelin Jr. (1999)
J Natl Cancer Inst 91, 594-598
   Abstract »    Full Text »    PDF »
p53-mediated protective responses to UV irradiation.
M. L. Smith and A. J. Fornace Jr. (1997)
PNAS 94, 12255-12257
   Full Text »    PDF »
Modulation of Interleukin-6-induced Plasma Protein Secretion in Hepatoma Cells by p53 Species.
L. Wang, R. J. Rayanade, D. Garcia, K. Patel, H. Pan, and P. B. Sehgal (1995)
J. Biol. Chem. 270, 23159-23165
   Abstract »    Full Text »    PDF »
Ubiquitin-mediated Processing of NF-kappaB Transcriptional Activator Precursor p105.
A. Orian, S. Whiteside, A. Israël, I. Stancovski, A. L. Schwartz, and A. Ciechanover (1995)
J. Biol. Chem. 270, 21707-21714
   Abstract »    Full Text »    PDF »
Induction of apoptosis in HeLa cells by trans-activation-deficient p53..
Y Haupt, S Rowan, E Shaulian, K H Vousden, and M Oren (1995)
Genes & Dev. 9, 2170-2183
   Abstract »    PDF »
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms.
P. Jeffrey, S Gorina, and N. Pavletich (1995)
Science 267, 1498-1502
   Abstract »    PDF »
Changes in Human Papillomavirus Typing of Recurrent Respiratory Papillomatosis Progressing to Malignant Neoplasm.
D. J. Doyle, L. A. Henderson, F. E. LeJeune Jr, and R. H. Miller (1994)
Arch Otolaryngol Head Neck Surg 120, 1273-1276
   Abstract »    PDF »
Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53..
J Bargonetti, I Reynisdottir, P N Friedman, and C Prives (1992)
Genes & Dev. 6, 1886-1898
   Abstract »    PDF »
The rat genome contains a p53 pseudogene: detection of a processed pseudogene using PCR..
J E Hulla (1992)
Genome Res. 1, 251-254
   Abstract »    PDF »
Regulation of Transformation and the Cell Cycle by p53.
G.P. Zambetti, R.S. Quartin, J. Martinez, I. Georgoff, J. Momand, D. Dittmer, C.A. Finlay, and A.J. Levine (1991)
Cold Spring Harb Symp Quant Biol 56, 219-225
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)